I don't know a lot about science, but it does seem to me the lack of FDA recognition of BETonMACE.....that it could be something of a road block at least in terms of RVX being recognized by the market in the manner most of us seem to think it should be.  

On top of that I'd love to read some thoughts about Apabetalone having IND status, which the CKDnews article linked in my previous post says will accelerate the approval process.  It seems to me while we're all waiting for the FA to come out on BETonMACE, that the real driver could be CKD.